Imiphumela yesikhungo esiningi Isigaba III Ucwaningo lwezokwelapha lubonise ukuthi uma iziguli esezikhulile ezine-lymphocytic leukemia engapheli ( Cll ) ziphathwa ngomuthi omusha ohlosiwe ibrutinib uma kuqhathaniswa ne-regimen-bendamustine ebisebenza ngaphambilini ehlanganiswe ne-rituximab Izinga lokuqhubeka kwesifo le-mAb lehliswe kakhulu, elibonisa nokuthi i-rituximab ihlanganiswe ne-ibrutinib ngeke ilethe izinzuzo ezengeziwe ngaphezu kwe-ibrutinib kuphela.
I-CLL iwumdlavuza ovame kakhulu we-leukocyte kubantu asebekhulile. Ngo-2016, i-US FDA yagunyaza i-ibrutinib njengokwelashwa komugqa wokuqala kwe-CLL. Ucwaningo lwangaphambilini lubonise ukuthi i-ibrutinib iphumelela kakhulu kunesinye isidakamizwa se-chemotherapeutic chlorambucil, kodwa azikho izifundo eziqhathanise i-ibrutinib ne-bendamustine kanye ne-rituximab.
Icala labhalisa iziguli ezingama-547 ezindala ezineminyaka yobudala ephakathi neminyaka engama-71. I-1/3 yanikezwa ngezikhathi ezithile ukuthola i-bendamustine Tingjia Li rituximab, 1/3 yamukelwa nguLu rituximab kaNijia Li, 1/3 yedwa nguLu imatinib. Abaphenyi balandela izinyanga ezingama-38 eziphakathi.
Uma kuqhathaniswa ne-bendamustine plus rituximab (74% eminyakeni emi-2), ibrutinib kanye ne-rituximab (88% eminyakeni emi-2) kanye ne-ibrutinib iyodwa (2 Ngonyaka, ama-87%) iziguli zazinezinga elide lokusinda ngaphandle kwenqubekela phambili (isiphetho sokuqala socwaningo ). Kodwa-ke, ucwaningo alutholanga mehluko emazingeni okusinda jikelele ala maqembu amathathu eminyakeni emi-2.
Uma kuqhathaniswa nokwamukela ibrutinib kuphela, ukungeza i-rituximab ku-ibrutinib akubonakali kukuthuthukisa ukubikezela. Sekukonke, iziguli ziphendule kahle kuzo zonke izindlela ezintathu zokwelashwa. Izinga lokuphendula jikelele leziguli ezithola i-bendamustine kanye ne-rituximab lalingama-81%, kanti iziguli ezithola ibrutinib kanye ne-rituximab kuya kuma-93% nguLu iziguli ngazinye ezithola ukwelashwa kwe-imatinib kwakungu-94%.
Yize izinga lokuqedwa ngokuphelele kwe-leukemia kusetshenziswa i-bendamustine kanye ne-rituximab laliphezulu, lo mehluko awuzange uhumushe ube ngamazinga okusinda angcono noma amanani aphansi okubuyela emuva. Ngakho-ke qaphela lapho ukhetha izidakamizwa.
Kodwa-ke, ibrutinib ihlotshaniswa nemiphumela emibi efana ne-atrial fibrillation kanye nezinhliziyo ezingavamile ezandisa ubungozi bokushaywa unhlangothi nezinye izifo zenhliziyo. Isiguli sinaka ukuqapha isimo senhliziyo ngesikhathi sokusetshenziswa.
https://medicalxpress.com/news/2018-12-ibrutinib-outperforms-chemoimmunotherapy-older-patients.html
